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Abstract
Formation of capillary blood vasculature is a critical requirement for native as well as engineered 
organs and can be induced in vitro by co-culturing endothelial cells with fibroblasts. However, 
whether these fibroblasts are required only in the initial morphogenesis of endothelial cells or 
needed throughout is unknown, and the ability to remove these stromal cells after assembly could 
be useful for clinical translation. In this study, we introduce a technique termed CAMEO 
(Controlled Apoptosis in Multicellular Tissues for Engineered Organogenesis), whereby 
fibroblasts are selectively ablated on demand, and utilize it to probe the dispensability of 
fibroblasts in vascular morphogenesis. The presence of fibroblasts is shown to be necessary only 
during the first few days of endothelial cell morphogenesis, after which they can be ablated 
without significantly affecting the structural and functional features of the developed vasculature. 
Furthermore, we demonstrate the use of CAMEO to vascularize a construct containing primary 
human hepatocytes that improved tissue function. In conclusion, this study suggests that transient, 
initial support from fibroblasts is sufficient to drive vascular morphogenesis in engineered tissues, 
and this strategy of engineering-via-elimination may provide a new general approach for achieving 
desired functions and cell compositions in engineered organs.
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Establishing new capillary beds is critical for supporting the metabolic demands and overall 
health of tissues and organs. This occurs not only in development, but throughout adult life 
in both regenerative and disease settings.[1] One mechanism by which such vessel beds form 
involves the spontaneous assembly of endothelial cells into interconnected networks, and 
ultimately, perfusable blood vessels.[2,3] Understanding and harnessing this vasculogenesis 
process for translational applications has been of keen interest.[4,5]
A key observation was that co-culture of endothelial cells with fibroblasts could induce 
endothelial cells to form vascular networks in vitro with minimal additional growth factors 
and cytokines.[6] In the presence of fibroblasts, endothelial cells spontaneously connected 
and developed multicellular structures associated with endothelial cell polarization, lumen 
formation, tubulogenesis, and vessel maturation following a process reminiscent of 
vasculogenesis.[7–11] Incorporating this process in microfluidic culture systems, it has more 
recently been shown that vasculogenic networks can integrate and support flow.[12–16]
The exact mechanism by which fibroblasts support vascular morphogenesis is not well 
understood, but the benefit is even conserved in vivo as incorporation of fibroblasts with 
endothelial cells in implantable constructs enhances in vivo vascularization.[17–20] The 
utility of such stromal populations in supporting cell function extends well beyond effects on 
endothelial cells, as they have been used in supporting stem cells culture, hepatocyte 
function, cardiac function, and more.[21–25] Therefore, stromal cells are a convenient, all-in-
one population of cells for many co-culture systems. However, it remains unclear whether 
the stromal cells are needed permanently to support these specialized cell functions, and in 
particular for endothelial cell vasculogenesis, whether they are required only during the 
initial morphogenetic events.
To address this question, we developed a technique termed CAMEO (Controlled Apoptosis 
in Multicellular Tissues for Engineered Organogenesis) which allows for a temporal control 
over the ablation of a select cell population, such as fibroblasts, within a 3D multicellular 
tissue after a short period of co-culture. This technique repurposes the inducible caspase-9 
(iCasp9) kill-switch gene that was originally developed as a fail-safe for T-cell therapies.
[26–28] By combining CAMEO with our microfluidic vasculogenesis model, we demonstrate 
that transient, initial support from fibroblasts is sufficient to drive functional 
neovascularization in engineered tissues. We then apply this insight to engineer vascularized, 
perfusable liver tissues embedded with human primary hepatocytes. Our approach of 
“engineering-via-elimination” provides new opportunities for not only studying the time 
dependencies of cell populations for processes such as vasculogenesis as demonstrated here, 
but also engineering vasculature in multicellular organ-specific tissues where the presence of 
fibroblasts may be undesirable.
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2. Results and Discussion
2.1 Fibroblasts Enhance Self-Assembly of a Perfused Vasculature in Microfluidic Devices
We first set out to establish a system that enables the 3D morphogenesis of an endothelial 
cell and fibroblast co-culture to result in a self-assembled, perfusable vascular network 
connected to microfluidic channels. Building on a previously reported device that we 
originally designed to study angiogenesis in vitro,[29,30] we developed a new iteration that 
supports vasculogenesis. This new microfluidic device consists of a polydimethylsiloxane 
(PDMS) silicone-based mold bonded to a glass coverslip that features a central tissue 
chamber (cells plus extracellular matrix) through which two endothelial cell-lined vessels 
can be perfused. To achieve this arrangement, briefly, two guides on the side of the PDMS 
device were designed for the insertion of two parallel needles (300 μm in diameter and 1mm 
apart) that traverse the central chamber (Figure 1a). Once the needles were inserted, a 
fibrinogen solution containing human umbilical vein endothelial cells (HUVECs) and 
growth-arrested human dermal fibroblasts (HDFs) were added into the tissue chamber with 
thrombin. Once the fibrinogen polymerized into fibrin, the needles were removed to create 
two hollow, microfluidic channels. These channels were then seeded with additional 
HUVECs to line the walls in a monolayer. This procedure resulted in the formation of two 
parallel, endothelialized vessels that could be instantly perfused with media and provide 
nutrients to the cells in the surrounding ECM.
To understand how different densities of fibroblasts would affect the vascular morphogenesis 
of a given number of endothelial cells, we co-cultured HUVECs (3 million cells/mL) with 
various concentrations of HDFs (0, 1, 3, and 6 million cells/mL) for 7 days in the fibrin 
surrounding the needle-molded endothelial channels (Figure 1b). HUVECs alone were able 
to make branching networks suggestive of functional vasculature (Figure 1c), but when 
perfused with a fluorophore-conjugated dextran solution (500 kDa) introduced to one of the 
microfluidic channels, these structures were unable to transport dextran. Only when HDFs 
were added to the HUVEC culture did we observe highly branched networks that were able 
to transport the dextran solution through the self-assembled vessels (Figure 1b, c). 
Furthermore, co-cultures with higher densities of HDFs (3:3 and 3:6 HUVEC:HDF) yielded 
the highest average percentage of perfused vessels (Figure 1d). While the average diameter 
of perfused self-assembled vessels (~45 μm) was similar regardless of the density of HDFs 
(Figure 1e(i)), increasing the density of fibroblasts resulted in a higher density of perfusable 
vasculature as well as a wider distribution of perfused vessel diameters (Figure 1e(ii)). At 
the highest concentration of HDFs (3:6 ratio), the engineered tissue was well vascularized all 
throughout its thickness after the 7-day co-culture (Figure 1f), which prompted us to use this 
ratio for the rest of the study.
To visualize the process of vasculogenesis in our microfluidic devices, we seeded GFP-
labeled HUVECs in the needle-molded microfluidic channels to distinguish them from the 
non-labeled HUVECs in the bulk fibrin gel. Fixing samples at different times and staining 
with Ulex Europaeus Agglutinin (UEA) lectin (which labels all HUVECs) allowed us to 
monitor the process of vascular network formation. As early as day 1, we observed GFP-
HUVECs with individual protrusions that started to form intercellular connections (Figure 
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2a). After 3 days in culture, some HUVECs from the microfluidic channels (GFP-labeled) 
had migrated into the bulk gel and formed chimeric networks with the (unlabeled) HUVECs 
in the bulk ECM (Figure 2b). Some of these self-assembled structures became perfusable by 
day 3, and the percentage of perfused vessels continued to increase over time, achieving 
~80% by day 7 (Figure 2c). Interestingly, the average diameters of the perfused vessels in 
the network remained steady after day 3 (Figure 2d). Together, these data suggest that the 
vascularization process inside our devices involves both the self-assembly of the bulk 
HUVECs, and invasion of HUVECs from the microfluidic channels to form a fully 
interconnected, perfusable vasculature consisting of both the originally templated, larger 
channels and the self-assembled vasculogenic network.
2.2 CAMEO Allows for a Selective Removal of Fibroblasts from Co-Culture
To ablate fibroblasts on demand from the developing co-culture, we utilized a synthetically 
engineered, inducible caspase-9 (iCasp9) that was originally developed as a safeguard 
against acute graft-versus-host disease (GVHD) and rare cytokine release syndrome (CRS) 
induced by T-cell therapies to treat cancer.[27,28] Briefly, iCasp9 is a transgene based on 
human caspase 9 that features a mutated FKBP12 domain (F36V) that can be dimerized with 
AP20187, an otherwise inert small molecule chemical inducer of dimerization (CID).[28] 
Upon dimerization, the iCasp9 proteins become activated, initiating the cascade of caspase-
based apoptotic pathways. Since the first description of iCasp9, several clinical studies 
demonstrated the effectiveness, specificity, and safety of the iCasp9-CID system.[27]
Using this inducible transgene, we established iCasp9-HDFs, and characterized the 
effectiveness of iCasp9 in these cells. We seeded iCasp9-HDFs on tissue culture plastic, 
allowed the cells to form a confluent monolayer before adding different concentrations of 
CID. Even at the lowest concentration of CID used (5 nM), the levels of cellular ATP 
dropped precipitously within 2–4 hours, suggesting the onset of apoptosis (Figure S1, 
Supporting Information). In addition, the rapidity of ATP loss increased with increasing CID 
concentration. Overnight treatment of 10 nM CID resulted in an average of ~96% reduction 
of iCasp9-HDFs in culture compared to the vehicle control (0.002% ethanol) (Figure 3a, b).
To understand whether the ablation of the fibroblasts could induce an inflammatory response 
in endothelial cells, we co-cultured the iCasp9-HDFs with endothelial cells, triggered 
apoptosis with CID, and examined the localization of Nuclear Factor Kappa-light-chain-
enhance of activated B cells (NFκB), a TLR-associated marker of the inflammation in 
HUVECs.[31–33] Whereas the majority of HUVECs treated with 10 ng/mL TNF-α (positive 
control) showed nuclear localization of NFκB as early as 4 hours and persisted through 48 
hours post-treatment, we only observed baseline levels similar to vehicle treatment (~10%) 
of nuclear NFκB positive HUVECs at 4 hours post-CID treatment and undetectable 
differences at later time points, suggesting that the HUVECs are not activated by the 
apoptosis of nearby iCasp9-HDFs (Figure S2, Supporting Information).
To examine the temporal and selective control of the iCasp9-HDFs in a 3D system, we co-
cultured mRuby-LifeAct-HUVECs with iCasp9-HDFs (GFP) in our microfluidic platform. 
After 7 days of co-culture, the cells formed a robust vasculature network as previously 
observed above, and then we added 10 nM of CID (or the vehicle control) to the media. We 
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observed iCasp9-HDFs starting to contract and round up as early as 1 hour post CID 
addition and the loss of GFP signal (due to photobleaching and the loss of protein 
production in apoptotic cells) between 5–10 hours post CID addition (Figure 3c and Movie 
S1, Supporting Information). Interestingly, the rounding event was preceded by a pulse of 
contraction of the fibroblasts and the surrounding tissue (Movie S1), consistent with 
reported caspase-induced ROCK1 activation and ROCK1-mediated actin-myosin 
contraction.[34,35] Remarkably, we did not observe any immediate, noticeable deterioration 
of the vascular structure during this massive elimination of HDFs, despite the HUVECs 
being, in some cases, in direct contact with the dying cells (Figure S3, Supporting 
Information).
2.3 Transient Co-Culture with Fibroblasts is Sufficient to Support Vasculogenesis.
To understand the dependence of endothelial cells on fibroblasts for vasculogenesis, we co-
cultured HUVECs with iCasp9-HDFs in our microfluidic devices and ablated the HDFs with 
CID at different time points (day 0, 1, 3, and 5) during the 7-day culture period (Figure 4a). 
Because a small population of HDFs (~4%) remain after CID treatment, we growth-arrested 
the cells with mitomycin C before co-culture to prevent their ability to proliferate and 
repopulate the co-culture over this week-long study. When HDFs were ablated within an 
hour after the completion of the device seeding (day 0), HUVECs were still able to form a 
network by day 7, but the resulting structure was minimally interconnected (Figure 4b, c), 
and none of these structures could transport dextran, indicating incomplete vascular 
morphogenesis similar to HUVEC-only cultures (Figure 4d). Removing HDFs at day 1 
resulted in a few perfusable structures by day 7, but most devices still showed little to no 
perfusion. Removing HDFs at day 3 or day 5 yielded highly interconnected and perfusable 
endothelial networks that were comparable to the control networks in which HDFs were 
never ablated. The average diameter of the perfused vessels was comparable as well for all 
conditions except the day 0-deletion condition, although the distribution of the vessel 
diameters in the day-1-deletion condition was more dispersed. Similar observations were 
also made with iCasp9-transduced human lung fibroblasts (iCasp9-HLFs) where the 
HUVECs were able to self-assemble into perfusable vasculature with only 3 days of co-
culture with iCasp9-HLFs (Figure S4, Supporting Information), suggesting that this short-
lived dependency on fibroblast support is not specific to HDFs. All together, these data 
suggested that the presence of fibroblasts during the first 1–3 days of co-culture is critical 
for the functional vasculogenesis of endothelial cells, but the fibroblasts can be ablated 
thereafter without structurally affecting the resulting vasculature. With this observation, we 
termed the technique “Controlled Apoptosis in Multicellular Tissues for Engineered 
Organogenesis,” or CAMEO.
Given that fibroblasts are important effectors of ECM remodeling, we hypothesized that 
HDFs may support vascular morphogenesis through their early effects on the ECM. To 
address this hypothesis, we first characterized the stiffness of the tissues during vascular 
network formation using nanoindentation and assessed the effect of CAMEO on these 
mechanical properties. Co-culturing HUVECs and iCasp9-HDFs for 3 days resulted in 
tissues with a Young’s modulus averaging ~0.75 kPa, which was substantially stiffer than 
acellular fibrin gels (~0.1 kPa) (Figure 4d). Over the next 4 days (days 3–7), these tissues 
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continued to stiffen, reaching an average Young’s Modulus of ~3 kPa at day 7. In contrast, 
when we induced apoptosis of iCasp9-HDFs at day 3 through CAMEO, the tissues did not 
further stiffen (~1 kPa at d7). These data suggest that there is substantial ECM remodeling 
during culture, and that the changes in ECM are primarily driven by the presence of 
fibroblasts.
To begin to examine whether HDFs might contribute molecular changes to the ECM during 
the first days of culture that might support later vascular morphogenesis, we looked to 
specific ECMs that could be deposited by the fibroblasts. One important matrix protein 
deposited by fibroblasts during early stages of ECM remodeling is fibronectin, which also 
has been shown to be important for vascular morphogenesis.[36–38] Therefore, we examined 
the role of fibronectin in our platform by generating siRNA-mediated fibronectin-
knockdown (FN-KD) iCasp9-HDFs and co-culturing them with HUVECs in the 
microfluidic devices for 3 days before CID treatment (Figure 4e). The density of self-
assembled endothelial networks was significantly reduced for HUVECs cocultured with the 
FN-KD iCasp9-HDFs as compared to scrambled siRNA-treated controls. Furthermore, 
HUVECs cocultured with FN-KD iCasp9-HDFs failed to generate any perfusable 
vasculature, whereas those cocultured with control iCasp9-HDFs yielded perfusable 
vasculature (Figure 4f, g), although to a lower extent than previously seen with wildtype 
HDFs (Figure 1d) likely due to inherent siRNA cytotoxicity in primary cells. Together, this 
suggests that the continuation of vascular morphogenesis after the removal of fibroblasts is 
contingent on provisional ECMs produced by the fibroblasts during the early days of co-
culture.
2.4 CAMEO Enhances Function of Vascularized, Engineered Hepatic Tissues.
Given that fibroblasts are only transiently required for supporting the formation of a 
functional vasculature, we asked whether CAMEO could be used in the vascularization of 
tissue constructs with organ-specific parenchymal cells without negatively affecting the 
function of the parenchymal cells. To investigate this, we employed a tri-culture system 
consisting of HUVECs, iCasp9-HDFs, and primary human hepatocytes in our microfluidic 
device. After 5 days of tri-culture, the devices were treated with CID to ablate the iCasp9-
HDFs, or with the vehicle control. All samples were fixed at day 7 to evaluate vascular 
perfusion (Figure 5a). In both groups, HUVECs formed perfusable vasculature that 
permeated the hepatocyte-laden construct (Figure 5b). To evaluate whether the hepatocytes 
remained functional after CID treatment, levels of albumin and urea, markers for hepatic 
protein synthesis function and nitrogen metabolism, respectively, were measured in the 
media. Removal of the iCasp-9 HDFs did not negatively affect the secretory functions of the 
hepatocytes in our devices (Figures 5c, d); in fact, we observed a statistically higher level of 
secreted albumin and urea at day 7 in CAMEO devices versus the vehicle control, 
suggesting potential benefits of removing the fibroblast population in the engineered liver 
constructs.
2.5 Discussion
In this study, we explored the dependence of endothelial cells on fibroblasts for forming 
perfusable vasculature by investigating whether a transient exposure to fibroblasts in a 3D 
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co-culture system is sufficient to drive endothelial cell morphogenesis. Whereas previous 
studies have shown that fibroblasts contribute to key morphogenetic steps during the 
formation of endothelial cell networks in vitro,[36] our study suggests that fibroblasts are 
only required to initiate the process of vascular network formation, which continues to 
develop in a semi-autonomous fashion even after fibroblasts are ablated. With CAMEO, we 
demonstrated that self-assembly of HUVECs into perfusable vasculature benefits from the 
presence of fibroblasts during the first several days of co-culture, but is undisturbed when 
fibroblasts are ablated as early as 3 days after the co-culture period. Indeed, HUVECs 
cultured alone formed loose networks that could not mature further into perfusable beds. 
While transient fibroblast co-culture was sufficient to support endothelial assembly of a 
perfusable vascular network, additional studies will be required to fully characterize whether 
later stages of vascular function, such as barrier or anti-coagulation functions, will require 
additional cell-cell interactions or will remain unaffected.
There are several known mechanisms through which stromal cells can promote vascular 
morphogenesis. Fibroblasts have been shown to secrete proangiogenic factors in the context 
of wound healing and tissue regeneration.[39–41] Nonetheless, previous studies have reported 
that simply transferring conditioned media from stromal cell monocultures to endothelial 
cells does not induce vascularization to the same extent as seen in co-culture settings. 
Although some studies have reported success in vascularizing small (100–200 μm thickness) 
tissues using microfluidic systems with separate, neighboring microcompartments for 
endothelial cells and fibroblasts,[42,43] a study by Griffith et al. highlighted that the paracrine 
support of vascular morphogenesis from fibroblasts decreases dramatically with the distance 
between ECs and fibroblasts in separate co-culture systems,[41] revealing the unique benefits 
of a directly mixed co-culture for vascularizing larger tissues. Indeed, fibroblasts are known 
to actively remodel their surrounding ECM via the expression of matrix metalloproteinases 
(MMPs) and tissue inhibitors of metalloproteinases (TIMPs), and to deposit various ECMs 
such as fibronectin and collagen type III.[36,44–46] Particularly, fibronectin has been 
described as a provisional matrix in development and wound healing that is important for 
angiogenesis, vasculogenesis, and vascular remodeling.[47–49] With siRNA knockdown, we 
demonstrated that the initial fibronectin deposition from fibroblasts to the co-culture matrix 
is critical for HUVECs to further develop perfusable vascular networks after the ablation of 
fibroblasts. This suggests that ECM deposition by the fibroblasts in the early days of co-
culture may be a critical cue that primes endothelial cells to continue the later stages of 
vascular morphogenesis without further support from fibroblasts.
Recent advancements in the tissue engineering field have enabled various types of tissues 
and organoids to be engineered, including brain, kidney, heart, and liver.[23,24,50–52] A main 
challenge in the field remains in appropriately vascularizing these tissues.[41] While using 
fibroblast-endothelial cell co-culture methods can contribute to addressing this challenge, 
fibroblasts are a population of highly heterogenous, uncharacterized cells that could 
potentially introduce undesirable effects such as tissue contraction, stiffening, and fibrosis.
[53–57] Therefore, a vascular engineering technique that relies minimally on these cells may 
be desirable for clinical translation. Here, we were able to demonstrate the use of CAMEO 
in generating engineered liver constructs featuring dense, perfusable vasculature and a 
minimal population of fibroblasts. Notably, the tissues with the fibroblasts ablated at day 5 
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using CAMEO seemed to have enhanced secretory functions of the human primary 
hepatocytes compared to tissues with intact fibroblasts at day 7, highlighting unexpected 
potential benefits of our CAMEO platform. There are many factors that might have 
contributed to the improved hepatocyte function following fibroblast ablation. First, 
improved hepatocyte function may have been a result of reduced tissue-stiffening following 
fibroblast ablation, consistent with other reports that lower matrix stiffness improves primary 
hepatocyte function.[58–61] Second, it has been previously shown that the interaction 
between endothelial cells and hepatocytes can promote hepatocyte function, maintenance, 
and regeneration.[62–65] Removing the fibroblasts from the hepatocyte-HUVEC-HDF tri-
culture system could enhance hepatocyte-HUVEC interactions, resulting in increased 
albumin and urea biosynthesis. Lastly, the high density of fibroblasts in non-ablated cultures 
may compete with hepatocytes for nutrients. Regardless, CAMEO may prove to be a useful 
strategy to optimize co-culture conditions for engineered tissues.
Previously, inducible apoptosis transgenes like iCasp9 were developed and primarily only 
used as a “fail-safe” for cell-based therapies involving T-cells,[27] MSCs,[66] and stem cells.
[67] In this study, we repurposed this suicide transgene and demonstrated its utility for 
studying cell-cell interactions as well as the subsequent impact on the functional 
vascularization of engineered tissues. CAMEO may offer general utility in applications 
beyond those demonstrated here. CAMEO could be used in culture settings, for example to 
eliminate xenogenic feeder-layer fibroblasts that are still widely used to cultivate embryonic, 
induced, and hematopoietic stem cells.[68] In tissue engineering, it may be useful to 
eliminate not only stromal populations, but also other cell populations that might have only a 
transient utility as well. Despite the enormous potential of this approach, further 
investigation of the induced apoptosis process and the clearing of apoptotic bodies will be 
needed to accurately evaluate the clinical translatability of CAMEO.
3. Conclusion
In summary, the CAMEO platform enabled by the synthetic kill-switch transgene, iCasp9, 
allowed for on-demand control over the specific removal of fibroblasts in our endothelial 
cell-fibroblast vasculogenesis model. Using this system, we demonstrated that only a 
transient co-culture with fibroblasts is sufficient for the endothelial cells to carry on and 
complete functional vascular morphogenesis, and then used these insights to generate 
functionally vascularized liver tissues with a minimal fibroblast population and improved 
secretory functions. This approach of “engineering-via-elimination” provides not only new 
opportunities for studying and engineering vasculature for a variety of applications, but more 




HUVECs (pooled from 4 donors, Lonza) were cultured in Endothelial Growth Medium-2 
(EGM-2, Lonza) and used before P7. HDFs (single donor; Lonza) were cultured in 
Fibroblast Growth Medium-2 (FGM-2, Lonza) and used before P10. Hepatic aggregates 
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were cultured as described previously.[23,69] Briefly, cryopreserved primary human 
hepatocytes (Lot ZGF; BioreclamationIVT) were thawed and immediately plated with 
iCasp9-HDFs in a 1:1 ratio in AggreWells (400 μm pyramidal microwells) and cultured for 3 
days in maintenance media containing 10% (v/v) fetal bovine serum (FBS) (Gibco), 1% 
(v/v) ITS supplement (insulin, transferrin, sodium selenite; BD Biosciences), glucagon (70 
ng/mL), dexamethasone (0.04 μg/mL), 0.015 M HEPES, and 1% (v/v) penicillin-
streptomycin (Invitrogen) in DMEM with 4.5 g/L glucose (Corning Cellgro).
Lentiviral Transduction:
iCasp9-HDFs and LifeAct-Ruby-HUVECs were generated using pMSCV-F-del 
Casp9.IRES.GFP (gift from David Spencer, Addgene plasmid #15567) and 
pLenti.PGK.LifeAct-Ruby.W (gift from Rusty Landsford, Addgene plasmid #51009), 
respectively. Briefly, individual plasmids were co-transfected into HEK-293T cells with 
pVSVG, pRSV-REV, and pMDLg/pRRE using the calcium phosphate transfection method. 
Supernatants containing the assembled viruses were collected after 48 hours and precipitated 
using PEG-IT (SBI). The concentrated viral pellet was resuspended in PBS and stored in 
−80°C. HDFs and HUVECs were transduced in growth media overnight with the 
appropriate lentiviral titers that had been optimized for minimal changes in cell morphology 
and proliferation. The cells were then washed in PBS the next day and fed with fresh growth 
media for expansion. For iCasp9-HDFs, GFP+ population (top 30%) was selected via flow-
assisted cytometry (FACSMelody, BD Biosciences) where the samples were first gated to 
exclude debris and cell doublets.
Device Assembly and Cell Seeding:
The molds for the 2-channel microfluidic devices (2 cm × 1 cm × 0.3 cm) were constructed 
using stereolithography (Proto Labs). Polydimethylsiloxane (PDMS) was cured at a standard 
mixing ratio overnight at 60°C in the mold, and individual devices were cut and plasma-
bonded to glass slides. To enhance ECM bonding to PDMS, the surface inside the tissue 
chamber of the devices was functionalized with 0.01% poly-L-lysine and 1% glutaraldehyde 
following plasma-activation and washed overnight in DI water. On the day of seeding, 
devices were soaked in 70% ethanol (EtOH) and dried. Acupuncture needles (300 μm 
diameter) (Hwato) were blocked in 0.1% (w/v) bovine serum albumin (BSA) (Sigma) in 
phosphate buffer saline (PBS) for 45 minutes and inserted through the two needle guides. 
Devices with needles were UV-sterilized for 15 minutes.
On the day of device seeding, HDFs or iCasp-9 HDFs were growth-arrested with 10 μg/mL 
mitomycin C in FGM-2 for 2.5 hours and thoroughly washed 5 times in FBM, in order to 
prevent the small population of HDFs (~4%) that remain after CID treatment from 
proliferating and repopulating the co-culture. We note that mitomycin C-arrested and 
untreated HDFs performed similarly in their ability to support vascular morphogenesis, and 
we used the growth-arrested HDFs for the current study. Both HUVECs and HDFs were 
lifted from culture plates using TrypLE Express (Gibco), centrifuged at 200 g for 4 minutes, 
and resuspended to a concentration of 20 million cells/mL in EGM-2. A solution of 
HUVECs (3 million cells/mL), HDFs or iCasp-9 HDFs (0, 1 million, 3 million, or 6 million 
cells/mL), fibrinogen (2.5 mg/mL), thrombin (1 U/mL) in EGM-2 was prepared for the bulk 
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hydrogel region of each device. For the devices with hepatocytes, a solution of HUVECs (3 
million cells/mL), iCasp-9 HDFs (total of 6 million cells/mL), hepatic aggregates (0.36 
million aggregates/mL with about 150 hepatocytes per aggregate), fibrinogen (2.5 mg/mL), 
thrombin (1 U/mL) was made in a 1:1 media mixture of EGM-2 and hepatocyte maintenance 
media. After the addition of thrombin, the solution was quickly injected into the tissue 
chamber, and the devices were repeatedly rotated while the solution crosslinked. 
Appropriate media was added to each well of the device, and the devices were placed in the 
incubator (37°C, 5% CO2). After 15 minutes, the needles were carefully ablated from the 
devices to create 300 μm hollow channels between the wells. Each channel of the device was 
seeded with additional HUVECs at 2 million cells/mL for at least 5 minutes on each side 
(top and bottom) in the incubator. Each device received 200 μL of appropriate media daily 
and cultured on the rocker inside the incubator.
Vessel Network Analysis:
All devices were fixed with 4% PFA for 30 minutes on a rocker and washed with PBS 
overnight at 4°C. The devices were then blocked in 3% BSA overnight at 4°C. Lectin (UEA 
DyLight 649, Vector Labs) was diluted in the blocking solution at 1:100 and added to the 
devices for another 4°C overnight incubation. Devices were then washed overnight with PBS 
at 4°C and kept in PBS with 0.02% (w/v) sodium azide at 4°C until imaging.
Before imaging, a solution of 500 kDa fluorescein isothiocyanate (FITC)- or 
tetramethylrhodamine isothiocyanate (TRITC)-conjugated dextran (0.15 mg/mL) was added 
to one of the microfluidic channels to generate a pressure gradient between the two channels 
of the device. All device images were then captured by a Leica SP8 confocal microscope 
(Leica, Wetzlar, Germany) using either a Leica 10x/0.30NA W U-V-I WD-3.60 Water or 
25x/0.95NA W VISIR WD-2.50 Water objective and Leica LAS X imaging software. 
Within experimental runs, the same laser intensities and settings were applied to all samples.
A custom MATLAB script was used to study properties of the vascular network (refer to 
Supporting Information for the code). The script imports a .tif image stack with a surface 
marker in one channel, in this case lectin, and the fluorescent dye in another, FITC- or 
TRITC-dextran. The aspect ratio of each image is adjusted so that each voxel is equally 
sized in all directions. Since our image resolution is higher in-plane (x- and y-axes) than 
along the depth (z-axis), this step typically results in a reduction in the number of pixels in 
the plane and an increase in the number of stack layers. The 3D volume of the cell surface 
marker channel is then smoothed using a spatial-domain Gaussian kernel to reduce noise in 
the Lectin channel.
The script relies on user inputs to generate binary images of the complete vascular network 
from the Lectin signal, and the perfused network according to the FITC-Dextran. First, the 
user selects a 2D region of interest between the two needle-molded channels on the device, 
and performs contrast-limited adaptive histogram equalization (CLAHE) on both signals for 
each z slice.[70] This step is performed to overcome a substantial loss in signal with depth of 
the volume.
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The user then specifies a luminance threshold for each channel and is able to move between 
different images in the z stack to best capture the vessel structure and perfusion of FITC-
Dextran. For the fluorescent dye, the signal is processed using only this specified uniform 
threshold to capture the regions of perfusion. For the Lectin channel, which exhibits poorer 
contrast, the user first selects a liberal threshold to segment the 3D volume. The script 
refines this initial segmentation for each slice using distance regularized level set evolution 
(DRLSE) with a double well potential (see full code for setup of the iterative segmentation 
refinement).[71] The DRLSE-segmented slices are merged to form the final volume of the 
full vessel network. Any holes in the Lectin volume are filled and islands smaller than ~50 
μm3 are removed.
From the identified Lectin network, a 3D medial axis skeleton is generated using homotopic 
thinning.[72,73] This is further converted into a graph with links representing the vessel 
structures, and nodes to identify branching and terminal points of the vessels.[73] Links are 
further characterized as perfused and non-perfused vessels based on the overlap of the 
binarized FITC-Dextran with the vessel network. Links with <25% perfusion are classified 
as non-perfused links. We report the average length of all links from the Lectin skeleton. The 
vessel radii are calculated based on the distance between the surface and the medial skeleton 
of the graph links, and the mean diameters for all vessels, as well as only perfused vessels, 
are reported. The percentages reported for branching nodes represent the fraction of 
branching nodes out of all nodes. The user can toggle through the z-stack of the binary 
channels overlaid on the original images, as well as overlaid on each other to confirm 
accuracy.
2D Viability and Inflammation Assays:
For the ATP assay, iCasp9-HDFs were plated in monolayer (8,500 cells/well in a 96-well 
plate). On the next day, cultures were dosed with CID (B/B homodimerizer aka AP20187) 
(Takara) at concentrations of 5, 50 or 500 nM and assayed for ATP levels using the 
CellTiter-Glo Luminescent Cell Viability Assay (Promega) according to the manufacturer’s 
instructions. For the cell-counting assay, iCasp9-HDFs were first mitomycin-treated for 2.5 
hours at 10 μg/mL and washed 3 times with FBM. Then, the cells were plated at 60,000 
cells/well in 24-well plates and cultured overnight in the incubator. On the next day, the 
wells were treated with either 10 nM CID or ethanol vehicle and cultured overnight in the 
incubator. These wells were then fixed with 4% PFA, washed with PBS, stained with DAPI 
(1:1000) (Sigma), and stored at 4°C. The nuclei of the cells were imaged with a Nikon TE 
200 microscope with a Nikon 20x/0.50NA objective and Spot Imaging 5.3 software. Cell 
nuclei were counted using CellProfiler to compare cell counts between vehicle and CID 
treatment.[74] For visualization of the cell bodies, some wells were stained with Alexa Fluor 
568 Phalloidin (1:200) (Life Technologies) and imaged with a Leica SP8 confocal 
microscope (Leica, Wetzlar, Germany) using a Leica 25x/0.95NA W VISIR WD-2.50 Water 
objective and Leica LAS X imaging software.
For the inflammation assay, 16-well chamber slides (Lab-Tek) were first coated with human 
fibronectin (Corning) at 10 μg/mL. For CID and vehicle conditions, each well was seeded 
with 7,000 HUVECs and 14,000 iCasp9-HDFs in EGM-2 media, and the cells were allowed 
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to attach and spread overnight. On the next day, we treated the wells with fresh EGM-2 
media containing either CID (10 nM) or vehicle. For the positive control condition, we 
added 7,000 HUVECs in each well in EGM-2 media, and on the next day, we seeded the 
wells with fresh EGM-2 media containing human recombinant TNF-α (R&D Systems) at 10 
ng/mL. In all conditions, cells were fix at 4, 12, 24, or 48 hours post treatment with 4% PFA. 
No media was changed between treatment and fixation. The fixed samples were 
permeabilized with 0.25% Triton X-100 for 10 minutes and blocked with 3% BSA for 1 
hour at room temperature. The samples were then stained with rabbit NFκB primary 
antibody (1:500) (Cell Signaling, D14E12) and UEA lectin (1:500) for 1 hour at room 
temperature, followed by secondary goat anti-rabbit Alexa Fluor 568 (1:1000) and DAPI 
(1:1000) staining overnight at 4C. Samples were stored in PBS at 4C until imaging. Samples 
were imaged by a Leica SP8 confocal microscope (Leica, Wetzlar, Germany) using a 25x/
0.95NA W VISIR WD-2.50 Water objective and Leica LAS X imaging software. The 
percentage of endothelial cells with nuclear NFκB was calculated by manually counting the 
total number of UEA-positive endothelial cells and the number of UEA-positive and nuclear 
NFκB -positive endothelial cells.
3D Culture Live Imaging:
Microfluidic devices with LifeAct-Ruby HUVECs and iCasp9-HDFs (GFP) were made and 
cultured for 7 days as described above. Then, the devices were transferred to a custom-made 
Petri dish that limits media evaporation. Media was changed to EGM-2 containing OxyFluor 
(Oxyrase) at a 1:100 dilution. Right before the start of imaging, either CID (10 nM) or 
vehicle was added to the devices and the petri dish was transferred into the microscope 
environmental chamber preconditioned to 37°C, 5% CO2, and 100% humidity. A 150 μm 
stack was imaged in each device by a Yokogawa CSU-10/Zeiss Axiovert 200M inverted 
spinning-disk microscope using a Zeiss 10x/0.45NA Air objective every 30 minutes for 18 
hours. The capture was automated using Metamorph 7.8.9.0 (Molecular Devices).
Nanoindentation Characterization:
Acellular fibrin gels and fibrin gels with HUVECs and iCasp9-HDF at 3:6 HUVEC:HDF 
ratio were prepared as described above in 2 mm diameter PDMS wells. Nanoindentation 
characterization was performed using a Piuma Nanoindenter system (Optics 11, Westwood, 
MA). The spherical indentation probe has a diameter size approximately 100 μm with 
cantilever spring constant k ~ 0.5 N/m. Samples were immersed in EGM2 medium and 
measurements were performed at indentation depth of 10 μm and displacement speed of 
5μm/s with 4–5 repeats for each condition. The Young’s moduli of these samples were 
calculated using the built-in Piuma software by fitting force-indentation curves to the 
Hertzian contact mechanics model, assuming a Poisson ratio of 0.5 for incompressible 
materials. Optics11 DataViewer software was used for data analysis. Acellular fibrin gels 
were measured at day 3 and tissues with HUVECs and iCasp9-HDFs were measured at day 
3, 4, or 7. For the tissues measured at day 4 or day 7, CID (10 nM) or vehicle was added to 
the media at day 3.
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Co-culture with Fibronectin Knockdown Fibroblasts:
iCasp9-HDFs were plated in 35mm dishes and allowed to expand to ~50% confluence. On 
the morning of transfection, media was replaced with an antibiotic-free media. At the end of 
the day, dishes were transfected with 20 pM of either human FN1 siRNA or human 
scrambled siRNA in a SMARTpool format (Dharmacon). siRNA was diluted in OPTI-MEM 
(Gibco) media and mixed with Lipofectamine RNAiMAX (Invitrogen) in OPTI-MEM. 
Mixtures were incubated at room temperature for 5 minutes, after which they were added 
dropwise to the cell dishes and incubated for 24 hours. On the next day, the cells were 
washed with FBM 5 times. Microfluidic devices with HUVECs and iCasp9-HDFs (treated 
with fibronectin or scramble siRNA) in fibrin were prepared as described above at 3:6 
HUVEC:HDF ratio and cultured for 7 days in EGM-2. At day 3, all the devices were treated 
with 10 nM of CID. Devices were fixed at day 7 and imaged for vessel network analysis as 
described above.
Hepatocyte Functional Assays:
On days 1, 3, 5, and 7, cultured media from the devices was collected and stored at −80°C. 
Supernatant was thawed to room temperature and assayed for human albumin using an 
enzyme-linked immunosorbent assay (ELISA) (Bethyl Laboratories) and 3,3’,5,5’-
tetramethylbenzidine (TMB, Thermo Fisher), as well as urea using a colorimetric 
(diacetylmonoxime) assay with acid and heat (Stanbio Labs).
All triculture devices were fixed with 4% PFA for 30 minutes on a rocker and washed with 
PBS overnight at 4°C. The devices were permeabilized with 0.15% Triton-X for 30 minutes 
on a rocker and washed with PBS 3 times. The devices were then blocked in 3% BSA 
overnight at 4°C. Dylight 649 labeled UEA (Vector Laboratories) and primary antibody for 
rabbit anti-human arginase-1 (Sigma, HPA003595) were diluted in the blocking solution at 
1:200 and 1:100 respectively and added to the devices overnight at 4°C. The devices were 
washed with PBS overnight at 4°C. Goat anti-rabbit Alexa Fluor 568 secondary antibody 
was diluted in the blocking solution at 1:100 and added to the devices overnight at 4°C. 
Devices were then washed overnight with PBS overnight at 4°C and kept in PBS with 0.02% 
(w/v) sodium azide at 4°C until imaging. A FITC-conjugated 500 kDa dextran solution (1.5 
mg/mL) was added to the devices as described above right before imaging. All device 
images were then captured by a Leica SP8 confocal microscope (Leica, Wetzlar, Germany) 
using either a Leica 10x/0.30NA W U-V-I WD-3.60 Water or 25x/0.95NA W VISIR 
WD-2.50 Water objective, and Leica LAS X imaging software.
Image Processing:
Max projection images used in figures were assembled and processed using Imaris 9.2.1 
(Bitplane). Intensity of stack images was depth compensated by utilizing a built-in 
autocorrelation correction Matlab plug-in (MathWorks). The dextran channels were 
smoothed using the Gaussian Filter that used a 3.89 μm filter width in order to make 
perfused channels more clearly visible in figures (Figure S5, Supporting Information). 
Thresholding and gamma correction were applied to all images. Both the UEA lectin and 
TRITC- Dextran were false-colored to red and cyan, respectively. Only unprocessed images 
were used in the image analysis, explained above. For images containing hepatocytes, false 
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coloring was applied to UEA lectin, FITC Dextran and Arg1 as red, cyan, and green, 
respectively. We applied uniform volumetric masks that were thresholded to denoise images 
due to antibody aggregation and fluorophore bleed through. These corrections were applied 
to the Dextran and Arg1 channels in all hepatocyte images.
Statistical Analysis:
All data are presented as mean ± standard deviation. At least three independent samples 
were analyzed for quantified sections. All statistical significance was determined using 
Prism (GraphPad, San Diego, CA). CID-induced cell count reduction in 2D was quantified 
by a two-tailed Welch’s t-test. Hepatocyte function data (albumin and urea), vascular 
network metrics for FN-KD experiments, and nanoindentation results were analyzed by 
unpaired two-tailed t-tests. All other mean analyses were performed using ordinary one-way 
ANOVA and, where appropriate, followed by Tukey’s honest significance test to evaluate 
statistical significance (P < 0.05).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fibroblasts enhance self-assembly of a perfused vasculature in a 3D microfluidic device. a) 
Rendering depicting (i) the process of seeding the microfluidic device with a fibrin gel 
containing HUVECs and HDFs cast around two needle-molded, endothelialized 
microfluidic channels and (ii) a close-up illustration of the formed tissue inside the 
microfluidic device. b) Representative max projections of devices fixed on day 7 with 
varying HUVEC:HDF ratios. Endothelial networks (red) were perfused with 500 kDa 
dextran (cyan) through one parent channel to visualize connected luminal networks. c) 
Quantification of the percentage of branching network nodes from total nodes to evaluate 
network interconnectedness. Each point represents one device. d) Quantification of the 
percentage of luminal segments that are perfused to the total segments between the channels. 
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e) (i) Quantification of the average diameter of perfused vessel segments for each condition, 
and (ii) the individual vessels of each ratio condition summed into bins and normalized to 
the bin with the greatest count. # represents where data points removed due to no vessels 
being perfused in those devices. f) Multiphoton max projection of a representative 3:6 ratio 
device. **: p < .01, ****: p < 0.0001, ns = not significant. Scale bars = b) 150 μm and f) 100 
μm.
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Daily fixations show vasculogenesis formation and functionality. a) (i) Representative 
images of growth progression from multicellular structures to functionally connected 
vasculature. GFP-expressing HUVECs (green) were seeded in the needle lumen only and 
eventually complex with the endothelial cells originating in the bulk gel. (ii) 2.5x zoomed 
images of the center of the devices. (iii) Same devices shown in (i) with dextran perfusion 
(cyan) shown along with UEA lectin (red). b) Quantification of percentage of branching 
nodes, c) percentage of vessels perfused, and d) average diameter of perfused vessels in 
devices. # represents where data points removed due to no vessels being perfused in those 
devices. *: p < 0.05, ****: p < 0.0001, ns = not significant. Scale bars a) (i) and (iii) = 150 
μm and a) (ii) = 50 μm.
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CAMEO allows for a selective removal of fibroblasts from co-culture. a) iCasp-HDFs plated 
on 2D wells, treated with a vehicle control or CID for 24 hours, fixed, and imaged. Cells 
stained with phalloidin (white) and DAPI (blue). b) Quantified cell density of vehicle 
control- and CID-treated cells. c) Time-lapse images of both device conditions in the 
microfluidic device. Scale bars = 100 μm.
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Transient co-culture with fibroblasts is enough to drive vascular morphogenesis. a) 
Experimental timeline. b) Representative max projections of devices treated with CID or 
vehicle control on a designated day and fixed on day 7. Devices were stained with UEA 
lectin (red) and perfused with dextran (cyan). c) Quantification of (i) percentage of 
branching nodes, (ii) percentage of perfused vessel segments, and (ii) average vessel 
diameter of perfused vessels. # represents where data points removed due to no vessels being 
perfused in those devices. d) Young’s modulus of HUVEC-iCasp9-HDF co-culture tissues 
treated with CID or vehicle at day 3. Dotted line represents the average Young’s modulus of 
acellular fibrin gel at day 3 (~0.1 kPa). e) Experiment timeline. f) Representative max 
projection images of dextran-perfusion (cyan), HUVECs (UEA lectin, red) and iCasp9-
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HDFs and their apoptotic bodies (GFP, white) at day 7. g) Quantification of (i) percentage of 
structures that are perfused with dextran and (ii) density of the self-assembled network. *: p 
< 0.05, **: p < 0.01, ***: p < 0.001, ****: p < 0.0001, ns = not significant. Scale bars = b) 
150 μm, and f) 50 μm.
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CAMEO enhances function of vascularized engineered hepatic tissues. a) Experimental 
timeline. b) (i) Representative max projections of dextran-perfused (cyan) vehicle control- 
and CID-treated devices stained for UEA lectin (red) and human arginase 1 (green), and (ii) 
2.5x images. c) (i) Quantification of secreted human albumin and (ii) urea production in 
each device with mean line shown. Dotted line denotes day vehicle control and CID were 
dosed for 24 hours. *: p < 0.05, **: p < 0.01. Scale bars = b) (i) 150 μm and b) (ii) 50 μm.
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